These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

52 related articles for article (PubMed ID: 8276503)

  • 1. Unwanted effects of ciprofloxacin in Indian population.
    Grover JK
    Indian J Physiol Pharmacol; 1993 Jul; 37(3):232-4. PubMed ID: 8276503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adverse reactions associated with aminopenicillins in Indian population.
    Grover JK; Tyagi D
    Indian J Physiol Pharmacol; 1993 Jul; 37(3):247-8. PubMed ID: 8276508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adverse drug reactions to fluoroquinolones at a tertiary care hospital in northern India.
    Uppal R; Jhaj R; Malhotra S
    J Assoc Physicians India; 1998 Nov; 46(11):946-7. PubMed ID: 11229222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pattern of adverse drug reactions due to cancer chemotherapy in a tertiary care teaching hospital in Nepal.
    Mallik S; Palaian S; Ojha P; Mishra P
    Pak J Pharm Sci; 2007 Jul; 20(3):214-8. PubMed ID: 17545106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety of ciprofloxacin. A review.
    Rahm V; Schacht P
    Scand J Infect Dis Suppl; 1989; 60():120-8. PubMed ID: 2667105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cutaneous adverse drug reactions: a 9-year study from a South Indian Hospital.
    Sushma M; Noel MV; Ritika MC; James J; Guido S
    Pharmacoepidemiol Drug Saf; 2005 Aug; 14(8):567-70. PubMed ID: 15937869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adverse drug reaction monitoring of ciprofloxacin in pediatric practice.
    Karande SC; Kshirsagar NA
    Indian Pediatr; 1992 Feb; 29(2):181-8. PubMed ID: 1592498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of adverse drug reactions with commonly prescribed drugs in different hospitals of Kathmandu valley.
    Jha N; Bajracharya O; Namgyal T
    Kathmandu Univ Med J (KUMJ); 2007; 5(4):504-10. PubMed ID: 18604084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adverse drug reactions in a south Indian hospital--their severity and cost involved.
    Ramesh M; Pandit J; Parthasarathi G
    Pharmacoepidemiol Drug Saf; 2003 Dec; 12(8):687-92. PubMed ID: 14762985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adverse drug reactions among inpatients in a north Indian referral hospital.
    Uppal R; Jhaj R; Malhotra S
    Natl Med J India; 2000; 13(1):16-8. PubMed ID: 10743370
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adverse drug reactions to treatments for ocular toxoplasmosis: a retrospective chart review.
    Iaccheri B; Fiore T; Papadaki T; Androudi S; Janjua S; Bhaila I; Stephen Foster C
    Clin Ther; 2008 Nov; 30(11):2069-74. PubMed ID: 19108794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A prospective study of adverse drug reactions in a dermatology department.
    Ganeva M; Gancheva T; Lazarova R; Tzvetanova Y; Hristakieva E
    Methods Find Exp Clin Pharmacol; 2007 Mar; 29(2):107-12. PubMed ID: 17440627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiretroviral induced adverse drug reactions in Iranian human immunodeficiency virus positive patients.
    Khalili H; Dashti-Khavidaki S; Mohraz M; Etghani A; Almasi F
    Pharmacoepidemiol Drug Saf; 2009 Sep; 18(9):848-57. PubMed ID: 19551698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Severe adverse drug reactions in psychiatric inpatients treated with neuroleptics.
    Bender S; Grohmann R; Engel RR; Degner D; Dittmann-Balcar A; Rüther E
    Pharmacopsychiatry; 2004 Mar; 37 Suppl 1():S46-53. PubMed ID: 15052514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new respiratory fluoroquinolone, oral gemifloxacin: a safety profile in context.
    Ball P; Mandell L; Patou G; Dankner W; Tillotson G
    Int J Antimicrob Agents; 2004 May; 23(5):421-9. PubMed ID: 15120718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
    Hurwitz BJ; Jeffery D; Arnason B; Bigley K; Coyle P; Goodin D; Kaba S; Kirzinger S; Lynch S; Mandler R; Mikol D; Rammohan K; Sater R; Sriram S; Thrower B; Boateng F; Jakobs P; Wash MB; Bogumil T
    Clin Ther; 2008 Jun; 30(6):1102-12. PubMed ID: 18640466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. WHO multinational study of three misoprostol regimens after mifepristone for early medical abortion.
    Honkanen H; Piaggio G; Hertzen H; Bártfai G; Erdenetungalag R; Gemzell-Danielsson K; Gopalan S; Horga M; Jerve F; Mittal S; Thi Nhu Ngoc N; Peregoudov A; Prasad RN; Pretnar-Darovec A; Shah RS; Song S; Tang OS; Wu SC;
    BJOG; 2004 Jul; 111(7):715-25. PubMed ID: 15198763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative bioavailability of two brands of ciprofloxacin.
    Seth SD; Beotra A; Seth S
    J Assoc Physicians India; 1995 May; 43(5):327-30. PubMed ID: 9081961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intermediate dose metoclopramide is not more effective than standard dose metoclopramide for patients who present to the emergency department with nausea and vomiting: a pilot study.
    Cham S; Basire M; Kelly AM
    Emerg Med Australas; 2004 Jun; 16(3):208-11. PubMed ID: 15228463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A prospective, controlled, randomized, non-blind, comparative study of the efficacy and safety of a once daily high dose of ceftriaxone plus ciprofloxacin versus thrice daily ceftazidime plus amikacin in empirical therapy for febrile neutropenic patients.
    Metallidis S; Kollaras P; Giannakakis T; Seitanidis B; Kordosis T; Nikolaidis J; Hatzitolios A; Nikolaidis P
    Eur J Intern Med; 2008 Dec; 19(8):619-24. PubMed ID: 19046729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.